Cargando…

Nivolumab in Renal Cell Carcinoma: Current Trends and Future Perspectives

Targeted agents form the backbone of most therapeutic strategies in advanced renal cell carcinoma (aRCC) but ultimately resistance develops and toxicity often leads to discontinuation of treatment, limiting the clinical benefits of these treatments. Nivolumab, a fully human IgG4 anti-PD-1 antibody,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ochoa, Cesar E., Joseph, Richard W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806048/
https://www.ncbi.nlm.nih.gov/pubmed/29468108
http://dx.doi.org/10.15586/jkcvhl.2018.102